Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #513 on Relmada Therapeutics Inc. (RLMD)
TheFinalCD
12/04/24 7:32 AM
#514 RE: Shift-4 #513
$RLMD PR during News Halt on Dec. 04 2024Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical…— NuntioBot (@NuntioBot) December 4, 2024
$RLMD PR during News Halt on Dec. 04 2024Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical…
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads